Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease
et al., JAMA Network Open,
Retrospective 62,525 hospitalized COVID-19 patients in France, showing that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
Hoertel et al., 15 Nov 2022, France, peer-reviewed, 5 authors, study period 24 January, 2020 - 30 November, 2021.
Abstract: Research Letter | Global Health
Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized
Patients With COVID-19 at Risk for Progression to Severe Disease
Nicolas Hoertel, MD, MPH, PhD; David R. Boulware, MD, MPH; Marina Sánchez-Rico, MD, PhD; Anita Burgun, PhD; Frédéric Limosin, PhD
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.